Demant A/S
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Søren Nielsen
- Full Time Employees
- 26,704
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Address
- Kongebakken 9 Smorum ZE Denmark 2765
- IPO Date
- Jun 24, 2011
- Website
- demant.com
- Similar Companies
- Business
- Demant A/S develops, manufactures and sells hearing healthcare products and equipment that help people with hearing loss connect and communicate with the world around them; core offerings span three business areas including Hearing Aids with brands such as Oticon, Bernafon and Sonic that provide advanced hearing devices incorporating AI-driven audio processing and chipsets; Hearing Care through the Audika Group delivering personalized retail hearing care services via a global network of clinics; and Diagnostics featuring equipment and services like audiometers, tympanometers and real-ear measurement systems from brands including Interacoustics, Maico and Grason-Stadler for hearing care professionals. The company operates in more than 30 countries, serves customers in over 130 markets primarily in Europe and North America, and employs more than 22,000 staff while generating annual revenue exceeding DKK 22 billion. Founded in 1904 and headquartered in Smørum, Denmark, Demant A/S lists on Nasdaq Copenhagen and is majority-owned by William Demant Invest A/S, the investment arm of the William Demant Foundation. Recent developments include the completion of its largest-ever acquisition of KIND Group on 1 December 2025 for EUR 700 million, adding approximately 650 hearing care clinics mainly in Germany, Switzerland, Austria, Luxembourg and Singapore to expand the Hearing Care footprint to over 4,500 clinics worldwide; a EUR 100 million loan from the Nordic Investment Bank in December 2024 to co-finance R&D investments in 2024 and 2025 focused on new hearing healthcare products, chipsets and AI algorithms; and an agreement signed to divest the Oticon Medical hearing implants business to Impilo for up to DKK 600 million, with closure expected by Q1 2026 to fully exit the implants segment.
Demant A/S (WILYY) Q4 2025 Earnings Call Transcript
Demant A/S (WILLF) Q2 2025 Earnings Call Transcript
Is Demant (WILYY) Stock Undervalued Right Now?
Demant A/S (WILLF) Q4 2024 Earnings Call Transcript
Best Momentum Stocks to Buy for March 26th
New Strong Buy Stocks for March 26th
New Strong Buy Stocks for March 19th
Best Momentum Stocks to Buy for March 11th
New Strong Buy Stocks for March 11th
Best Momentum Stocks to Buy for March 7th
New Strong Buy Stocks for March 7th
Best Momentum Stocks to Buy for March 4th
New Strong Buy Stocks for March 4th
Best Momentum Stocks to Buy for February 12th
Demant A/S (WILLF) Q4 2023 Earnings Call Transcript
Demant A/S (WILLF) Q2 2023 Earnings Call Transcript
Demant A/S (WILLF) Q3 2023 Earnings Call Transcript
The Scandinavian Shopping List In A Time Of Bargains